Potential predictors of chemotherapy response in ovarian cancer-How do we define chemosensitivity?

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 345-351

  O'Toole, S A ^a   Sheppard, B L ^a   Laios, A ^a   O'Leary, J J ^a   McGuinness, E P J ^b   D'Arcy, T ^b   Bonnar, J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

CD31; Chemotherapy response; MDR1; Ovarian cancer; Prognostic indicator; VEGF

Indexed keywords

VASCULOTROPIN;

ANALYSIS OF VARIANCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHI SQUARE TEST; CORRELATION COEFFICIENT; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846366392     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.039     Document Type: Article

References (48)

1. Hoskins W.J. Prospective on ovarian cancer. J. Cell. Biochem. Suppl. 23 (1995) 189-199
2. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of twenty-five major cancers in 1990. Int. J. Cancer 80 (1999) 827-841
3. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3 2 (1992) 65-71
4. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 6219 (1989) 58-61
5. Paweletz N., and Knierim M. Tumor-related angiogenesis. Crit. Rev. Oncol. Hematol. 9 3 (1989) 197-242
6. Ribatti D., Vacca A., Roncali L., and Dammacco F. Angiogenesis under normal and pathological conditions. Haematologica 76 4 (1991) 311-320
7. DeYoung B.R., Wick M.R., Fitzgibbon J.F., Sirgi K.E., and Swanson P.E. CD31: an immunospecific marker for endothelial differentiation in human neoplasms. Appl. Immunohistochem. 1 (1993) 97-100
8. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36 (1995) 127-137
9. Brustmann H., Riss P., and Naude S. The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: a quantitative histologic study. Gynecol. Oncol. 67 1 (1997) 20-26
10. Raspollini M.R., Amunni G., Villanucci A., Baroni G., Boddi V., and Taddei G.L. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int. J. Gynecol. Cancer 14 5 (2004) 815-823
11. Paley P.J., Staskus K.A., Gebhard K., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80 1 (1997) 98-106
12. Yamamoto S., Konishi I., Kuroda H., et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 76 9 (1997) 1221-1227
13. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147 1 (1995) 9-19
14. World Health Organization Offset Publication No. 48. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): WHO;1979.
15. Thigpen J.T., Ball H., Hummel S.J., and Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12 9 (1994) 1748-1753
16. Nakanishi Y., Kodama J., Yoshinouchi M., et al. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol. 16 3 (1997) 256-262
17. Hartenbach E.M., Olson T.A., Goswitz J.J., Mohanraj D., Twiggs L.B., and Carson L.F. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 121 2 (1997) 169-175
18. Orre M., and Rogers P.A. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumors of the ovary. Int. J. Cancer 84 2 (1999) 101-108
19. Shen G.H., Ghazizadeh M., Kawanami O., et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 83 2 (2000) 196-203
20. Ueda K., Cardarelli C., Gottesman M.M., and Pastan I. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicines, doxorubicin and vinblastine. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3004-3008
21. Bell D.R., Gerlach J.H., Kartner N., Buick R.N., and Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J. Clin. Oncol. 3 3 (1985) 311-315
22. Bourhis J., Goldstein L.J., Riou G., Pastan I., Gottesman M.M., and Benard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res. 49 18 (1989) 5062-5065
23. Liotta L.A., Kleinerman J., and Saidel G.M. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 34 5 (1974) 997-1004
24. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324 1 (1991) 1-8
25. Weidner N., Folkman J., Pozza F., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84 24 (1992) 1875-1887
26. Hollingsworth H.C., Kohn E.C., Steinberg S.M., Rothenberg M.L., and Merino M.J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147 (1995) 33-41
27. Sonmezer M., Gungor M., Ensari A., and Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int. J. Gynecol. Cancer 14 1 (2004) 82-88
28. Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., and Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83 12 (1998) 2528-2533
29. Brustmann H., and Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol. Oncol. 84 1 (2002) 47-52
30. Stone P.J., Goodheart M.J., Rose S.L., Smith B.J., DeYoung B.R., and Buller R.E. The influence of microvessel density on ovarian carcinogenesis. Gynecol. Oncol. 90 3 (2003) 566-571
31. Garzetti G.G., Ciavattini A., Lucarini G., et al. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 85 10 (1999) 2219-2225
32. Darai E., Bringuier A.F., Walker-Combrouze F., et al. CD31 expression in benign borderline, and malignant epithelial ovarian tumors: an immunohistochemical and serological analysis. Gynecol. Oncol. 71 (1998) 122-127
33. Obermair A., Wasicky R., Kaider A., et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett. 138 1-2 (1999) 175-182
34. Gadducci A., Viacava P., Cosio S., et al. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res. 23 1B (2003) 549-556
35. Ali-Fehmi R., Morris R.T., Bandyopadhyay S., et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am. J. Obstet. Gynecol. 192 3 (2005) 819-825
36. Orre M., Lofti-Miri M., Maners P., and Rogers P.A.W. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary. Br. J. Cancer 77 12 (1998) 2204-2209
37. Giatromanoali A., Koukourakis M.I., Theodossiou D., et al. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin. Cancer Res. 3 (1997) 2485-2492
38. Horak E.R., Leek R., Klenk N., et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340 (1992) 1120-1124
39. Gasparini G., Bonoldi E., Viale G., et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int. J. Cancer 69 (1996) 205-211
40. van Diest P.J., Zevering J.P., Zevering L.C., and Baak J.P. Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients. Pathol. Res. Pract. 191 1 (1995) 25-30
41. Holzmayer T.A., Hilsenbeck S., Von Hoff D.D., and Roninson I.B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst. 84 19 (1992) 1486-1491
42. Schondorf T., Scharl A., Kurbacher C.M., et al. Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas. Cancer Lett. 146 2 (1999) 195-199
43. Baekelandt M.M., Holm R., Nesland J.M., Tropé C.G., and Kristensn G.B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 20 (2000) 1061-1068
44. Van der Zee A., Hollema H., Suurmeijer A., et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13 1 (1995) 70-78
45. Roninson I.B. Molecular and Cellular Biology of Multidrug Resistance in Tumour Cells (1991), Plenum, New York
46. Coley H.M. Drug resistance studies using fresh human ovarian carcinoma and soft tissue sarcoma samples. Keio J. Med. 46 3 (1997) 142-147
47. Kavallaris M., Leary J.A., Barrett J.A., and Friedlander M.L. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett. 102 1-2 (1996) 7-16
48. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev., Cancer 3 10 (2003) 721-732